<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04932941</url>
  </required_header>
  <id_info>
    <org_study_id>MP1032-CT05</org_study_id>
    <secondary_id>2021-000344-21</secondary_id>
    <nct_id>NCT04932941</nct_id>
  </id_info>
  <brief_title>MP1032 Treatment in Patients With Moderate to Severe COVID-19</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter, Proof-of-concept, Phase IIA Study of MP1032 Plus Standard of Care vs Standard of Care in the Treatment of Hospitalized Participants With Moderate to Severe COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MetrioPharm AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MetrioPharm AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of MP1032 with standard of&#xD;
      care (SoC) verses placebo with SoC in hospitalized adults participants with moderate to&#xD;
      severe coronavirus disease 2019 (COVID-19).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Disease Progression at Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>The National Institute of Allergy and Infectious Diseases (NIAID) 8-point Ordinal Scale is an assessment of clinical status on a given study day and is defined as follows:&#xD;
Death&#xD;
Hospitalized, on invasive ventilation (mechanical ventilator and/or extracorporeal membrane oxygenation [ECMO])&#xD;
Hospitalized, on non-invasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, but requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care (used if hospitalization was extended for infection-control reasons)&#xD;
Not hospitalized, limitation on activities, and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities&#xD;
Disease progression defined as participants who are not alive or who have respiratory failure (participants who have a score of 2, 3, or 4 on the NIAID scale).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Disease Progression at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>The NIAID 8-point Ordinal Scale is an assessment of the clinical status on a given study day and the scale is defined as follows:&#xD;
Death&#xD;
Hospitalized, on invasive ventilation (mechanical ventilator and/or ECMO)&#xD;
Hospitalized, on non-invasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, but requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care (used if hospitalization was extended for infection-control reasons)&#xD;
Not hospitalized, limitation on activities, and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities&#xD;
Disease progression is defined as participants who are not alive or who have respiratory failure (participants who have a score of 2, 3, or 4 on the NIAID 8-point ordinal scale).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Disease Resolution at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>The NIAID 8-point Ordinal Scale is an assessment of the clinical status on a given study day and the scale is defined as follows:&#xD;
Death&#xD;
Hospitalized, on invasive ventilation (mechanical ventilator and/or ECMO)&#xD;
Hospitalized, on non-invasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, but requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care (used if hospitalization was extended for infection-control reasons)&#xD;
Not hospitalized, limitation on activities, and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities&#xD;
Disease resolution is defined as participants who are alive and have a score of 6, 7, or 8 on the NIAID 8-point ordinal scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality Rate at Day 28</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Clinical Status related to COVID-19 according to the NIAID 8-point Ordinal Scale at Day 28</measure>
    <time_frame>Baseline, Day 28</time_frame>
    <description>The NIAID 8-point Ordinal Scale is an assessment of the clinical status on a given study day and the scale is defined as follows:&#xD;
Death&#xD;
Hospitalized, on invasive ventilation (mechanical ventilator and/or ECMO)&#xD;
Hospitalized, on non-invasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, but requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care (used if hospitalization was extended for infection-control reasons)&#xD;
Not hospitalized, limitation on activities, and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Disease Resolution at Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>The NIAID 8-point Ordinal Scale is an assessment of the clinical status on a given study day and the scale is defined as follows:&#xD;
Death&#xD;
Hospitalized, on invasive ventilation (mechanical ventilator and/or ECMO)&#xD;
Hospitalized, on non-invasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, but requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care (used if hospitalization was extended for infection-control reasons)&#xD;
Not hospitalized, limitation on activities, and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities&#xD;
Disease resolution is defined as participants who are alive and have a score of 6, 7, or 8 on the NIAID 8-point ordinal scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality Rate at Day 14 and Day 60</measure>
    <time_frame>Day 14 and Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Clinical Status related to COVID-19 According to the NIAID 8-point Ordinal Scale at Day 14</measure>
    <time_frame>Baseline, Day 14</time_frame>
    <description>The NIAID 8-point Ordinal Scale is an assessment of the clinical status on a given study day and the scale is defined as follows:&#xD;
Death&#xD;
Hospitalized, on invasive ventilation (mechanical ventilator and/or ECMO)&#xD;
Hospitalized, on non-invasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, but requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care (used if hospitalization was extended for infection-control reasons)&#xD;
Not hospitalized, limitation on activities, and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants requiring Invasive Ventilation (Mechanical Ventilator and/or ECMO), or who are not Alive on Day 14 and Day 28</measure>
    <time_frame>Day 14 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in each category of the NIAID 8-point Ordinal Scale</measure>
    <time_frame>From Baseline up to Day 60</time_frame>
    <description>The NIAID 8-point Ordinal Scale is an assessment of the clinical status on a given study day and the scale is defined as follows:&#xD;
Death&#xD;
Hospitalized, on invasive ventilation (mechanical ventilator and/or ECMO)&#xD;
Hospitalized, on non-invasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, but requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care (used if hospitalization was extended for infection-control reasons)&#xD;
Not hospitalized, limitation on activities, and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to (First) Improvement of at least 1 Category on the NIAID 8-point Ordinal Scale</measure>
    <time_frame>From Baseline up to Day 28</time_frame>
    <description>The NIAID 8-point Ordinal Scale is an assessment of the clinical status on a given study day and the scale is defined as follows:&#xD;
Death&#xD;
Hospitalized, on invasive ventilation (mechanical ventilator and/or ECMO)&#xD;
Hospitalized, on non-invasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, but requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care (used if hospitalization was extended for infection-control reasons)&#xD;
Not hospitalized, limitation on activities, and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Odds Ratio for the Number of Participants with Clinical Status Improvement From Baseline on the NIAID 8-point Ordinal Scale at Day 14 and Day 28</measure>
    <time_frame>Baseline, Day 14 and Day 28</time_frame>
    <description>The NIAID 8-point Ordinal Scale is an assessment of the clinical status on a given study day and the scale is defined as follows; where higher score indicates improvement in the clinical status:&#xD;
Death&#xD;
Hospitalized, on invasive ventilation (mechanical ventilator and/or ECMO)&#xD;
Hospitalized, on non-invasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, but requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care (used if hospitalization was extended for infection-control reasons)&#xD;
Not hospitalized, limitation on activities, and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Duration of Hospitalization at Day 28 and Day 60</measure>
    <time_frame>From Baseline, Day 28 and Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants alive and testing negative for COVID-19 at Day 14, Day 28, and Day 60</measure>
    <time_frame>Day 14, Day 28 and Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with treatment emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 1 up to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Vital Sign Abnormalities</measure>
    <time_frame>Day 1 up to Day 60</time_frame>
    <description>Systolic and diastolic blood pressure, heart rate, respiration rate, oxygen saturation (SpO2), and body temperature) abnormalities will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Physical Examination Findings</measure>
    <time_frame>Day 1 up to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Laboratory Findings</measure>
    <time_frame>Day 1 up to Day 60</time_frame>
    <description>Abnormalities in haematology, coagulation, clinical chemistry, serum inflammatory, and urinalysis abnormalities will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of MP1032</measure>
    <time_frame>Pre-dose, 0.16, 0.33, 0.5, 1, 2, 8 and 24 hours post-dose at Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time curve from Time Zero (pre-dose) to last non-zero concentration (AUC0-t) of MP1032</measure>
    <time_frame>Pre-dose, 0.16, 0.33, 0.5, 1, 2, 8 and 24 hours post-dose at Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Elimination Rate Constant (K) of MP1032</measure>
    <time_frame>Pre-dose, 0.16, 0.33, 0.5, 1, 2, 8 and 24 hours post-dose at Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Body Clearance (CL) of MP1032</measure>
    <time_frame>Pre-dose, 0.16, 0.33, 0.5, 1, 2, 8 and 24 hours post-dose at Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vd) of MP1032</measure>
    <time_frame>Pre-dose, 0.16, 0.33, 0.5, 1, 2, 8 and 24 hours post-dose at Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration Prior to the Next Dose (Ctrough) of MP1032</measure>
    <time_frame>Pre-dose at Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Observed Plasma Concentration at Steady State of MP1032</measure>
    <time_frame>Pre-dose, 0.16, 0.33, 0.5, 1, 2, 8 and 24 hours post-dose at Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>MP1032</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive MP1032 300 milligrams (mg) twice daily (BID) with hospital selected SoC for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matched to MP1032 with hospital selected SoC for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP1032</intervention_name>
    <description>Hard gelatin capsules for oral administration.</description>
    <arm_group_label>MP1032</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules matched to MP1032 for oral administration.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Participant is admitted to hospital and has a positive severe acute respiratory&#xD;
             syndrome coronavirus type 2 (SARS-CoV-2) test by standard reverse&#xD;
             transcription-polymerase chain reaction (RT-PCR) assay or equivalent test&#xD;
&#xD;
          -  Participant has the presence of any symptom(s) suggestive of moderate or severe&#xD;
             systemic illness with COVID-19&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Participant, in opinion of the investigator, is not likely to survive &gt;=48 hours&#xD;
             beyond Day 1&#xD;
&#xD;
          -  Participant has a diagnosis of asymptomatic COVID-19, mild COVID-19, or critical&#xD;
             COVID-19 on Day 1&#xD;
&#xD;
          -  Participant has a documented medical history of infection with hepatitis A, B, C, or&#xD;
             with human immunodeficiency virus (with a detectable viral load and CD4 count &lt;500&#xD;
             cells per micro liter), or a documented active infection with tuberculosis.&#xD;
&#xD;
          -  The Participant has clinically significant electrocardiogram (ECG) abnormalities at&#xD;
             screening&#xD;
&#xD;
        Other protocol defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amy Freeman</last_name>
    <phone>+1 610 233 5695</phone>
    <email>amy.freeman@syneoshealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tina Lamberts</last_name>
    <email>tina.lamberts@syneoshealth.com</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>MP1032</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

